- Home
- NRK vs AUPH Comparison
NRK vs AUPH Comparison
Compare NRK & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRK | AUPH |
|---|---|---|
| Founded | 2002 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 878.5M | 1.6B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | NRK | AUPH |
|---|---|---|
| Price | $10.00 | $16.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 187.3K | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 4.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | N/A | ★ $265,808,000.00 |
| Revenue This Year | N/A | $21.76 |
| Revenue Next Year | N/A | $16.45 |
| P/E Ratio | ★ N/A | $29.59 |
| Revenue Growth | N/A | ★ 20.62 |
| 52 Week Low | $8.95 | $6.55 |
| 52 Week High | $11.09 | $16.54 |
Technical Indicators
Market Signals| Indicator | NRK | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 42.58 | 63.25 |
| Support Level | $9.92 | $16.00 |
| Resistance Level | $10.15 | $16.54 |
| Average True Range (ATR) | 0.07 | 0.44 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 54.55 | 83.01 |
Price Performance
Historical ComparisonAbout NRK Nuveen New York AMT-Free Quality Municipal Income Fund
Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.